Cargando...
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer
Angiogenesis remains a sensible target for pancreatic ductal adenocarcinoma (PDAC) therapy. VEGF, PDGF, FGF and their receptors are expressed at high levels and correlate with poor prognosis in human PDAC. Nintedanib is a triple angiokinase inhibitor that targets VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β s...
Guardado en:
| Publicado en: | Cancer Lett |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4450873/ https://ncbi.nlm.nih.gov/pubmed/25527450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.12.027 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|